Evaluation of pyrimidine/pyrrolidine-sertraline based hybrids as multitarget anti-Alzheimer agents: In-vitro, in-vivo, and computational studies.

[1]  A. Sadiq,et al.  Diclofenac derivatives as concomitant inhibitors of cholinesterase, monoamine oxidase, cyclooxygenase-2 and 5-lipoxygenase for the treatment of Alzheimer's disease: synthesis, pharmacology, toxicity and docking studies , 2022, RSC advances.

[2]  Imran Kazmi,et al.  Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine as Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease , 2022, ACS omega.

[3]  U. Rashid,et al.  Structural Modification, In Vitro, In Vivo, Ex Vivo, and In Silico Exploration of Pyrimidine and Pyrrolidine Cores for Targeting Enzymes Associated with Neuroinflammation and Cholinergic Deficit in Alzheimer's Disease. , 2021, ACS chemical neuroscience.

[4]  U. Rashid,et al.  Fluoxetine and sertraline based multitarget inhibitors of cholinesterases and monoamine oxidase-A/B for the treatment of Alzheimer's disease: Synthesis, pharmacology and molecular modeling studies. , 2021, International journal of biological macromolecules.

[5]  Yang Liu,et al.  Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease , 2021, Journal of Nanobiotechnology.

[6]  M. Matos.  Multitarget therapeutic approaches for Alzheimer's and Parkinson's disease: an opportunity or an illusion? , 2021, Future medicinal chemistry.

[7]  A. Hazrat,et al.  Neuroprotective Studies on Polygonum hydropiper L. Essential Oils Using Transgenic Animal Models , 2021, Frontiers in Pharmacology.

[8]  Shoaib Manzoor,et al.  A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review. , 2020, European journal of medicinal chemistry.

[9]  S. Davaran,et al.  Design, synthesis, biological evaluation, and docking study of novel dual-acting thiazole-pyridiniums inhibiting acetylcholinesterase and β-amyloid aggregation for Alzheimer's disease. , 2020, Bioorganic chemistry.

[10]  B. Hyman,et al.  Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.

[11]  S. Patassini,et al.  Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer's disease. , 2020, Biochemical and biophysical research communications.

[12]  Robin Kumar,et al.  Ajmalicine and Reserpine: Indole Alkaloids as Multi-Target Directed Ligands Towards Factors Implicated in Alzheimer’s Disease , 2020, Molecules.

[13]  O. Wirths,et al.  Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease , 2019, Expert opinion on therapeutic targets.

[14]  U. Rashid,et al.  Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents. , 2019, European journal of medicinal chemistry.

[15]  M. Zvěřová.  Clinical aspects of Alzheimer's disease. , 2019, Clinical biochemistry.

[16]  Shengtao Xu,et al.  Multi-target design strategies for the improved treatment of Alzheimer's disease. , 2019, European journal of medicinal chemistry.

[17]  F. A. Khan,et al.  Design, synthesis and bioevaluation of tricyclic fused ring system as dual binding site acetylcholinesterase inhibitors. , 2019, Bioorganic chemistry.

[18]  Wenmin Liu,et al.  Design, Synthesis, and Evaluation of Novel Ferulic Acid Derivatives as Multi-Target-Directed Ligands for the Treatment of Alzheimer's Disease. , 2018, ACS chemical neuroscience.

[19]  U. Rashid,et al.  Rational design and synthesis of dihydropyrimidine based dual binding site acetylcholinesterase inhibitors. , 2016, Bioorganic chemistry.

[20]  V. Andrisano,et al.  Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography. , 2016, Journal of medicinal chemistry.

[21]  Li Wang,et al.  Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.

[22]  Holger Jahn,et al.  Memory loss in Alzheimer's disease , 2013, Dialogues in clinical neuroscience.

[23]  Irene Bolea,et al.  Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.

[24]  T. Arendt,et al.  The cholinergic system in aging and neuronal degeneration , 2011, Behavioural Brain Research.

[25]  M. Meeter,et al.  Retrograde Amnesia for Autobiographical Memories and Public Events in Mild and Moderate Alzheimer's Disease , 2006, Journal of clinical and experimental neuropsychology.

[26]  M. Holden,et al.  Use of cholinesterase inhibitors in dementia , 2002 .

[27]  T. Thomas.  Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease , 2000, Neurobiology of Aging.

[28]  Heng Du,et al.  Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.